Richard B. Kim, MD, FRCPC, Division Chair
Dr. Kim received his medical degree from University of Saskatchewan, Canada in 1987. After completing an internship and residency training at Royal University hospital in Saskatoon Canada in 1991, he went on to carry out postdoctoral fellowship training in Clinical Pharmacology at Vanderbilt University.
In 1994, upon completion of his fellowship training, he remained at Vanderbilt Clinical Pharmacology as a faculty member until 2006. He is currently Professor and Chair of the Division of Clinical Pharmacology in the Department of Medicine at the University of Western Ontario in London, Canada. His research interest is that of understanding the molecular basis of interindividual differences in drug disposition and the application of such finding to the emerging field of Personalized Medicine.
Research areas under active investigation in his laboratory include that of drug transporters, CYP enzymes, and the pathways involved in the regulated expression of such proteins. He is a member of ASCPT, ISSX, and AAPS. He is an editor for the Medical Letter Handbook of Adverse Drug Interactions, and an associate editor for Molecular Pharmacology. He is a fellow of AAPS, and member of the American Society for Clinical Investigation (ASCI).

Publications
2000  2001  2002  2003  2004
<<<        >>>

Dishy V., Landau R., Sofowora G., Xie H.G., Smiley R.M., Kim R.B., Byrnes D.W., Wood A.J.J., and Stein C.M.: Beta2 adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics, 14:517-522, 2004. [Pubmed]

Haas D.W., Ribaudo H.J., Kim R.B., Tierney C., Wilkinson G.R., Gulick R.M., Clifford D.B., Hulgan T., Marzolini C., and Acosta E.P.: Pharmacogenetics of efavirenz and central nervous system side effects: An adult AIDS clinical trials group study. AIDS, 18:2391-2400, 2004. [Pubmed]

Ho R.H., Leake B.F., Roberts R.L., Lee W., and Kim R.B.: Ethnicity-dependent polymorphism in NTCP (SLC10A1) reveals a domain critical for bile acid substrate recognition. J. Biol. Chem., 279:7213-7222, 2004. [Pubmed]

Hoffmaster K.A., Turncliff R.Z., LeCluyse E.L., Kim R.B., Meier P.J., Brouwer K.L.: P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res., 21:1294-302, 2004.  [Pubmed]

Kim R.B: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: What's it all about? Clin. Pharmacol. Ther., 75:381-385, 2004.  [Pubmed]

Lee W. and Kim R.B.: Transporters and renal drug elimination. Annu. Rev. Pharmacolol. Toxicol., 44:137-166, 2004. [Pubmed]

Marzolini C., Paus E., Buclin T., and Kim R.B.: Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin. Pharmacol. Ther., 75:13-33, 2004. [Pubmed]

Marzolini C., Tirona R.G., and Kim R.B.: Pharmacogenomics of OATP and OAT families. Pharmacogenomics, 5:273-282, 2004. [Pubmed]

Sofowora G., Dishy V., Landau R., Xie H.G., Prasad H.C., Byrne D.W., Smiley R.M., Kim R.B., Wood A.J.J., and Stein C.M.: Alpha 1A-adrenergic receptor polymorphism and vascular response. Clin. Pharmacol. Ther., 75:539-545, 2004. [Pubmed]

Tirona R.G., Leake B.F., Podust L.M., and Kim R.B.: Identification of amino acids in rat pregnane X receptor that determine species-specific activation. Mol. Pharmacol., 65:34-44, 2004. [Pubmed]

Xie H.G., Wood A.J.J., Kim R.B., Stein C.M., and Wilkinson G.R.: Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics, 5:243-272, 2004. [Pubmed]